Background: Lung cancer is the most common cancer and remains the main death cause worldwide. The aim of study was to determinate the incidence and survival rate of lung cancer in a population of affiliates in a private institution (ONCOSALUD-AUNA). Method: In a dynamic cohort, the incidence of lung cancer was evaluated in a population of affiliates to ONCOSALUD -AUNA between 2008 -2013. Overall survival (OS) was evaluated in patients treated in ONCOSALUD e AUNA between 2000-2005 (n ¼ 114). The incidence rate was calculated based on new cases/persons-year of observation. The incidence rate standardized by age was calculated having the structure of the world standard population. OS was estimated using the Kaplan-Meier method and comparisons of survival curves were performed using the Log-rank or Breslow test. Results: The median age at affiliation was 33 years (range: <1, 98), 18.9% were under 15 years old, 5.6% were older than 64, and 55.7% were women. A total of 2,611,438.3 persons-year of observation was calculated and 394 affiliates (193 and 201 in women and men, respectively) were diagnosed with lung cancer. The median age at diagnosis was 70 years (range: 35, 98). The standardized incidence rate by age was 7.9 per 100,000 persons-year (6.5 and 10.0 in women and men per 100,000 persons-year, respectively), and 74 years cumulative risk was 1.0% (0.9 and 1.3% in women and men, respectively). For survival assessment, the median age at diagnosis was 69 years, 37.9% were women and 76.3% had advanced disease (CS III: 18.2% and CS IV: 58.1%). With a 10.6-year follow-up, the median survival was 0.62 years (CI95%: 0.46, 0.78). The OS rate at 5 and 10 years were 16.4% and 12.9%, no significant differences in relation to sex (p ¼ 0.118), age (<60 vs. >60 years: p ¼ 0.300) were observed, and it shows significant difference according clinical stage (CS I-II vs. IIIeIV: p < 0.001). Conclusion: The incidence rate of lung cancer in our population is slightly lower than reported by the IARC for the Peruvian population. The survival rate at 5 and 10 years is similar to reported by other series. Background: Brain metastases are present in 10 to 30 % of NSCLC patients sometime during the disease. The aim of our research is to identify the clinical pathological characteristics in patients with stage IIIB-IV related to the development of brain metastases. Method: 590 patients diagnosed with NSCLC stage IIIB-IV at our institution were included. Of these, 496 showed an advanced stage. The variables included in the analysis of patients with and without brain metastases were: gender, age, histology, smoking status and ECOG. The multivariate logistic regression model was used to identify factors related to brain metastases. Results: The development of brain metastasis was proportionally higher in women compared to men (77.7% vs 22.2%). Over 80% of patients presented ECOG of 0-1. Regarding histology, 60.32% were adenocarcinomas; 30% squamous, and 9.5% undifferentiated. 65% of patients were under 65 years old. 66.6% of patients were former smokers. Patients under 65 years old are at increased risk of developing brain metastases than older patients (HR¼0,5-IC95%¼ 0,6-1,16-p¼0,045). Adenocarcinoma histology is associated with an increased number of brain metastases development (OR ¼ 2.42 -95% CI ¼ 1.84 to 3.00 -p¼ 0.003). Conclusion: In this trial was observed that patients younger than 65 years and etiology of adenocarcinoma have a higher risk of developing brain metastases. Regarding gender, we observe an increased risk in men, however, the differences were not
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Oncologia, Instituto Oncologico de Cordoba, Cordoba/AR Background: Brain metastases are present in 10 to 30 % of NSCLC patients sometime during the disease. The aim of our research is to identify the clinical pathological characteristics in patients with stage IIIB-IV related to the development of brain metastases. Method: 590 patients diagnosed with NSCLC stage IIIB-IV at our institution were included. Of these, 496 showed an advanced stage. The variables included in the analysis of patients with and without brain metastases were: gender, age, histology, smoking status and ECOG. The multivariate logistic regression model was used to identify factors related to brain metastases. Results: The development of brain metastasis was proportionally higher in women compared to men (77.7% vs 22.2%). Over 80% of patients presented ECOG of 0-1. Regarding histology, 60.32% were adenocarcinomas; 30% squamous, and 9.5% undifferentiated. 65% of patients were under 65 years old. 66.6% of patients were former smokers. Patients under 65 years old are at increased risk of developing brain metastases than older patients (HR¼0,5-IC95%¼ 0,6-1,16-p¼0,045). Adenocarcinoma histology is associated with an increased number of brain metastases development (OR ¼ 2.42 -95% CI ¼ 1.84 to 3.00 -p¼ 0.003). Conclusion: In this trial was observed that patients younger than 65 years and etiology of adenocarcinoma have a higher risk of developing brain metastases. Regarding gender, we observe an increased risk in men, however, the differences were not statistically significant. Background: Inherited susceptibility for lung cancer (LC) has been described, a recent paper showed that 2.5% of LC patients (pts) carried a pathogenic germline variation in genes such ATM, TP53, BRCA2, EGFR, and PARK2. Some of those genes cause well recognized syndromes. Thus, GRCA for LC could help to identify a genetic predisposition syndrome, guide genetic testing, offering specific treatments and genetic counseling. Method: This is a retrospective and descriptive study. We performed a review of 66 medical records of LC pts diagnosed between 2011 and 2016. We collected age at diagnosis, smoking, previous cancer diagnosis, and family history (FH) for cancer: number of affected family members and sort of cancer. Genetic evaluation and testing was not available at time of first evaluation, but we tried to identify genetic syndromes according to the clustering pattern and NCCN criteria. Results: Mean age was 62.5 years (range 26-88y); 30 pts (45.5%) had FH with 46 affected relatives: 21 pts had at least one first degree affected member, only 2 pts had more than 3 affected members. Among the tumors, Breast cancer (BrCa) was found in 12 family members; one pt had a previous BrCa diagnosis at 33y; LC was found in 1 relative; 4 cases of colon cancer were described; 1 case was found for prostate and melanoma respectively. Other tumors were described, but they are not frequently associated to other genetic syndromes. We found no statistical differences on smoking between pts with or without FH. Pts with FH tended to be younger (p¼0.026). Based on the family assessment, 8 (10.6%) cases met NCCN criteria for genetic counseling and testing for BRCA and Homologous Recombination (HR) pathway genes. Conclusion: Unfortunately, age of diagnosis for family members was available in 8 out 46 cases, data available were taken from the first clinical assessment which limits this analysis. Even if the expected number of pts with inherited susceptibility to LC is low, a proper GRCA could improve the diagnosis of genetic syndromes. This could bring advantages, such as offering PARP inhibitors for Pts carrying mutations in HR pathway genes, cascade screening and set up prevention measures adapted for each gene risks. Finally, more extended genetic analysis could be offered based on clinical features of index cases. At our knowledge, GRCA clinics for LC is not frequent in Mexico, these results underline the importance of setting up this clinic at our center. Background: Despite nonesmall cell lung cancer (NSCLC) high prevalence and increasing incidence, evidence specific to the elderly and
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